Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 668-679

  Thunell, Stig ^a   Pomp, Erik ^b   Brun, Atle ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

5 amino levulinate synthase; Cytochrome P 450 enzyme system; Drug therapy; Porphyrias; Porphyrinogenicity; Porphyrogenicity

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; AMPHETAMINE; ATAMESTANE; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ENZYME; ENZYME INHIBITOR; EPHEDRINE; EXEMESTANE; FLUOROURACIL; FURAFYLLINE; GLUCOCORTICOID; HEME; LEVODOPA; METHOXSALEN; METOCLOPRAMIDE; OMEPRAZOLE; ORPHENADRINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TICLOPIDINE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE INTERMITTENT PORPHYRIA; ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CLINICAL FEATURE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG USE; DRUG UTILIZATION; HUMAN; LIVER CELL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BINDING; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

5-AMINOLEVULINATE SYNTHETASE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PORPHYRIA, ACUTE INTERMITTENT; PORPHYRINOGENS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 35248878486     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.0306-5251.2007.02955.x     Document Type: Article

References (67)

1. Kappas A, Sassa S, Anderson KE. The Porphyrias. In Stanbury, JB, Wyyngaarden, JB, Fredrickson, DS, Goldstein, JL, Brown, MS, eds. The metabolic basis of inherited disease, 5th edn. New York : McGraw-Hill Co., 1983 1301 84.
2. With TK. A short history of porphyrins and the porphyrias. Int J Biochem 1980 11 : 189 200.
3. Wetterberg L. Report on an international survey of safe and unsafe drugs in acute intermittent porphyria. In : Doss, M, Nawrocki, P, eds. Porphyrins in Human Diseases - Reports of the Discussions. Marbourg, Germany, 1976 191 202.
4. Moore MR, McColl KEL, Rimington C, Goldberg A. Disorders of porphyrin metabolism. New York and London : Plenum Co, 1987 144 54.
5. Hift RJ, Meissner PN, Meissner DM. Porphyria. [a Guide for People with Porphyria and Their Doctors.]. Cape Town : Medical Research Council and University of Cape Town Liver Research Centre. 1989.
6. Bonkovsky HL. Porphyrin and heme metabolism and the porphyrias. In Zakim, D, Poyer, TD, eds. Hepatology. A textbook of liver disease, 2nd edn. Philadelphia : W.B. Saunders. 1990 378 424.
7. Wilson JHP, de Rooij FWM. Gastro-intestinal, neurologic and psychiatric manifestations of acute porphyria. Turku, Finland : Leiras OY, 1995.
8. Anderson KE. The porphyrias. Some of the major drugs considered unsafe and safe in the acute porphyrias. In : Beers, MH, Berkow, MD, eds. The Merck Manual, 17th edn, Merck Research Laboratories, 1999 191.
9. Deybach JC. [Allowed and Contraindicated Drugs]. Centre Francais des Porphyries, Hospital Louis Mourier, Coulomb, Cedex, France 2000.
10. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 1992 71 : 1 13.
11. Gorchein A. Treatment of Parkinson's disease in a patient with acute intermittent porphyria. Br J Clin Pharmacol 1995 40 : 105 6.
12. Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. Clin Pharmacol Ther 1999 66 : 323 5.
13. Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria. A case report and review of the literature. Support Care Cancer 2001 9 : 465 6.
14. Moore MR, McColl KE. Drugs and the acute porphyrias. Trends Pharmacol Sci 1987 2 : 330 5.
15. Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol 1997 44 : 427 34.
16. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet 1997 349 : 1613 7.
17. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005 142 : 439 50.
18. Thunell S. Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab Invest 2000 60 : 509 40.
19. Thunell S. Genomic approach to acute porphyria. Physiol Res 2007 55 (Suppl 2 S43 66.
20. Lewis DF, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 2004 9 : 530 7.
21. Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004 4 : 1745 66.
22. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005 44 : 279 304.
23. Fraser DJ, Podvinec M, Kaufmann MR, Meyer UA. Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem 2002 277 : 34717 26.
24. Podvinec M, Handschin C, Looser R, Meyer UA. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci USA 2004 101 : 9127 32.
25. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999 284 : 757 60.
26. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 2000 38 : 493 504.
27. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001 41 : 123 43.
28. Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 2002 30 : 96 9.
29. Perez G, Tabares B, Jover R, Gomez-Lechon MJ, Castell JV. Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol Vitro 2003 17 : 643 9.
30. Guengerich FP. Human cytochrome enzymes. In : Ortiz de Montellano, PR, ed. Cytochrome P450: Structure, mechanism and biochemistry, 2nd edn. New York : Plenum Press, 1995 473 509.
31. Handschin C, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005 122 : 505 15.
32. Whitlock JP Jr., Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In : Ortiz de Montellano, PR, ed. Cytochrome P450: Structure, mechanism and biochemistry, 2nd edn. New York : Plenum Press, 1995 374.
33. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996 41 : 477 91.
34. Strolin BM, Ruty B, Baltes E. Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 2005 19 : 511 29.
35. Lahtela JT, Gachalyi B, Eksyma S, Hamalainen A, Sotaniemi EA. The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. Br J Clin Pharmacol 1986 21 : 19 26.
36. Strolin BM, Whomsley R, Baltes E. Induction of drug metabolizing enzymes and toxicological consequences in laboratory animals and humans: the example of thyroid hormone homeostasis. 15th International Symposium on Microsomes and Drug Oxidations; 4-9 July 2004, Mainz, Germany; Abstract S1-CH-12, P72, 2006.
37. Victor A, Lundberg PO, Johansson ED. Induction of sex hormone binding globulin by phenytoin. BMJ 1977 2 : 934 5.
38. Herzog AG. Reproductive endocrine considerations and hormonal therapy for men with epilepsy. Epilepsia 1991 32 (Suppl 6 S34 S37.
39. Sano J, Kawada H, Yamaguchi N, Kawakita M, Kobayashi K. Effects of phenytoin on serum gamma-glutamyl transpeptidase activity. Epilepsia 1981 22 : 331 8.
40. Scott AK, Jeffers TA, Petrie JC, Gilbert JC. Serum bilirubin and hepatic enzyme induction. BMJ 1979 2 : 310.
41. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987 33 : 139 44.
42. Nijhawan R, Wierzbicki AS, Tozer R, Lascelles PT, Patsalos PN. Antiepileptic drugs, hepatic enzyme induction and raised serum alkaline phosphatase isoenzymes. Int J Clin Pharmacol Res 1990 10 : 319 23.
43. Tutor-Crespo MJ, Hermida-Ameijeiras J, Tutor-Valcarce JC. [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]. Rev Neurol 2002 35 : 711 6.
44. Rapeport WG, McInnes GT, Thompson GG, Forrest G, Park BK, Brodie MJ. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol 1983 16 : 133 7.
45. Lecamwasam DS. Hepatic enzyme induction and its relationship to urinary d-glucaric acid excretion in man. Br J Clin Pharmacol 1975 2 : 546 8.
46. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989 28 : 373 87.
47. Hunter J, Maxwell JD, Carrella M, Stewart DA, Williams R. Urinary d-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet 1971 1 : 572 5.
48. Benedetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol Res 1995 32 : 177 87.
49. Ortiz de Montanello PR, Correia MA. Inhibition of cytochrome P450 enzymes. In : Ortiz de Montellano, PR, ed. Cytochrome P450: Structure, mechanism and biochemistry, 2nd edn. New York : Plenum Press, 1995 305 64.
50. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002 34 : 83 448.
51. Fontana E, Dansette PM, Poli SM. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005 6 : 413 54.
52. Rowland M, Tozer TN, eds. Clinical pharmacokinetics: Concepts and applications, 3rd edn. Philadelphia : Lippincott, Williams & Wilkins, 1995.
53. Savas U, Griffin KJ, Johnson EF. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. Mol Pharmacol 1999 56 : 851 7.
54. Rang HP, Dale MM, Ritter JM, Moore P, eds. Absorbtion, distribution and fate of drugs. In : Pharmacology, 5th edn. Edinburgh : Churchill Livingstone, 2003 91 105.
55. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptor pregnane X receptor, farnesoid Xactivated receptor, and constitutive androstane receptor. J Biol Chem 2002 277 : 2908 15.
56. Niesel HC. [Local anesthetics - maximum recommended doses]. Anaesthesiol Reanim 1997 22 : 60 2.
57. Clement R, Malinovsky JM, LeCorre P, Dollo G, Chevanne F, LeVerge R. Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intratechal and epidural administrations in rabbits under microdialysis. J Pharmacol Exp Ther 1999 289 : 1015 21.
58. Lewis DFV. Structural characteristics of human P450s in drug metabolism: QSARs and lipophilicityty profiles. Toxicology 2004 144 : 197 293.
59. Thunell S, Bjernevik K, Harper P, Thunell G. Patient's and Doctor's Guide to Medication. In : Acute porphyria, Thunell, S, eds. Stockholm : Swedish Porphyria Association, 2005.
60. Robert TL, Varella L, Meguid MM. Nutrition management of acute intermittent porphyria. Nutrition 1994 10 : 551 5.
61. Mustajoki P, Tenhunen R, Tokola O, Gothoni G. Haem arginate in the treatment of acute hepatic porphyrias. Br Med J (Clin Res Ed) 1986 293 : 538 9.
62. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991 86 : 1050 6.
63. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med 2006 119 : 801 24.
64. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study. Scand J Clin Lab Invest 2000 60 : 643 8.
65. Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 2002 62 : 288 97.
66. Waldenström J. [Porphyria studies]. Acta Med Scand Supplement, 1937 82 : 1 254.
67. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003 38 : 978 88.